{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:55:27Z","timestamp":1791356127406,"version":"4.3.1"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Atrial fibrillation (AF) is associated with a significantly increased risk of thromboembolic complications, including ischaemic stroke. Despite the dominant role of oral anticoagulants, low-molecular-weight heparins (LMWHs) are still used in selected clinical scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim of this review was to summarise the current clinical role of LMWHs in atrial fibrillation, with particular emphasis on available evidence, practical limitations and selected complex clinical scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review based on the analysis of available clinical trials, guidelines, and pharmacological data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Low-molecular-weight heparins are used primarily for bridging therapy and in situations where oral anticoagulation is temporarily contraindicated or not feasible. However, robust evidence supporting the long-term use of LMWHs for stroke prevention in atrial fibrillation remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low-molecular-weight heparins should not be considered standard chronic therapy for atrial fibrillation. Further studies are needed to better define optimal anticoagulation strategies in patients with atrial fibrillation, particularly in complex clinical settings such as active cancer and thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1853400","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:43:06Z","timestamp":1791355386000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-molecular-weight heparins in atrial fibrillation: clinical scenarios, limitations, and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Sabina","family":"M\u0119drek","sequence":"first","affiliation":[{"name":"Department of Cardio-Oncology, Centre of Postgraduate Medical Education","place":["Warsaw, Poland"]},{"name":"Department of Cardiology and Cardio-Oncology Unit, Subcarpathian Oncological Center","place":["Brzozow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zaborowska-Szmit","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumours, Maria Sk\u0142odowska-Curie National Research Institute of Oncology","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[{"name":"Department of Cardio-Oncology, Centre of Postgraduate Medical Education","place":["Warsaw, Poland"]},{"name":"Cardio-Oncology Unit, Maria Sk\u0142odowska-Curie National Research Institute of Oncology","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100026","DOI":"10.1016\/j.rpth.2022.100026","article-title":"Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study","volume":"7","author":"Ay","year":"2022","journal-title":"Res. Pr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.04.006","article-title":"Perioperative heparin bridging in atrial fibrillation patients requiring temporary interruption of anticoagulation: evidence from meta-analysis","volume":"25","author":"Ayoub","year":"2016","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/s0140-6736(01)05837-8","article-title":"Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial","volume":"358","author":"Bath","year":"2001","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1161\/CIRCULATIONAHA.114.013243","article-title":"Extracranial systemic embolic events in patients with nonvalvular atrial fibrillation: incidence, risk factors, and outcomes","volume":"132","author":"Bekwelem","year":"2015","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/s0140-6736(00)02085-7","article-title":"Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST study group. Heparin in acute embolic stroke trial","volume":"355","author":"Berge","year":"2000","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/pharmacy14010019","article-title":"Direct oral Anti-Xa anticoagulants and the future of factor XI\/FXIa inhibition: a new paradigm in thrombosis prevention","volume":"14","author":"Bernardi","year":"2026","journal-title":"Pharm. (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.thromres.2022.01.007","article-title":"Clinical characteristics, time course, and outcomes of major bleeding according to bleeding site in patients with venous thromboembolism","volume":"211","author":"Bikdeli","year":"2022","journal-title":"Thromb. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/eurjpc\/zwaa054","article-title":"Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management","volume":"28","author":"Boriani","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"A collaboration between multiple institutions to better investigate non-vitamin K antagonist oral anticoagulant use in atrial fibrillation investigators. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10937","DOI":"10.1038\/s41598-023-38071-3","article-title":"Impact of type of anticoagulant on clinical outcomes in cancer patients who had atrial fibrillation","volume":"13","author":"Chai-Adisaksopha","year":"2023","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/medicina57050444","article-title":"Percutaneous left atrial appendage occlusion: an emerging option in patients with atrial fibrillation at high risk of bleeding","volume":"57","author":"Cimmino","year":"2021","journal-title":"Med. Kaunas."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e44553","DOI":"10.1371\/journal.pone.0044553","article-title":"Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review","volume":"7","author":"Costantino","year":"2012","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fcvm.2020.00011","article-title":"Atrial cardiomyopathy: an unexplored limb of virchow's triad for AF stroke prophylaxis","volume":"7","author":"Darlington","year":"2020","journal-title":"Front. Cardiovasc Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jacc.2016.11.024","article-title":"2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American college of cardiology clinical expert consensus document task force","volume":"69","author":"Doherty","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1113\/JP286978","article-title":"Cellular and molecular cross-talk in atrial fibrillation: the role of non-cardiomyocytes in creating an arrhythmogenic substrate","volume":"604","author":"Dong","year":"2026","journal-title":"J. Physiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"B19","first-page":"2802","article-title":"Er det forskjell p\u00e5 lavmolekylaere hepariner? [is there a difference between low-molecular-weight heparins?]","volume":"125","author":"Eritsland","year":"2005","journal-title":"Tidsskr. Nor. Laegeforen"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.1007\/s00520-022-07136-w","article-title":"Anticoagulation and bleeding in the cancer patient","volume":"30","author":"Escobar","year":"2022","journal-title":"Support Care Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","article-title":"Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice","volume":"42","author":"Fareed","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3892\/ol.2022.13244","article-title":"Anticoagulation for atrial fibrillation in active cancer","volume":"23","author":"Farmakis","year":"2022","journal-title":"Oncol. Lett."},{"key":"B25","first-page":"35","article-title":"Study of the efficacy, safety and tolerability of low-molecular-weight heparin vs. unfractionated heparin as bridging therapy in patients with embolic stroke due to atrial fibrillation","volume":"9","author":"Feiz","year":"2016","journal-title":"J. VascInterv Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/phar.1937","article-title":"Anticoagulation bridge therapy in patients with atrial fibrillation: recent updates providing a rebalance of risk and benefit","volume":"37","author":"Garwood","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/s0894-7317(99)70105-7","article-title":"Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (the stroke prevention in atrial fibrillation [SPAF-III] study)","volume":"12","author":"Goldman","year":"1999","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/1538574406291820","article-title":"Peripheral arterial embolism: prevalence, outcome, and the role of echocardiography in management","volume":"40","author":"Gossage","year":"2006","journal-title":"Vasc. Endovasc. Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00392-024-02492-5","article-title":"Echocardiographic assessment of left atrial appendage morphology and function-an expert proposal by the German working group of cardiovascular ultrasound","volume":"114","author":"Hagendorff","year":"2025","journal-title":"Clin. Res. Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the european society of cardiology (ESC) developed with the special contribution of the european heart rhythm association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64s","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"109611","DOI":"10.1016\/j.thromres.2026.109611","article-title":"Patient adherence and satisfaction with self-administration of prophylactic low molecular weight heparin (LMWH) after orthopaedic trauma surgery: a prospective observational cohort study","volume":"259","author":"Horzum","year":"2026","journal-title":"Thromb. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/s0889-8588(05)70052-6","article-title":"Low-molecular-weight heparins","volume":"12","author":"Huang","year":"1998","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/0269216318815377","article-title":"Oral anticoagulation is preferable to injected, but only if it is safe and effective: an interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial","volume":"33","author":"Hutchinson","year":"2019","journal-title":"Palliat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1182\/bloodadvances.2023011235","article-title":"Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation","volume":"7","author":"Iyengar","year":"2023","journal-title":"Blood Adv."},{"key":"B37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4274\/tjh.2015.0271","article-title":"Warfarin dosing and time required to reach therapeutic international normalized ratio in patients with hypercoagulable conditions","volume":"33","author":"Kahlon","year":"2016","journal-title":"Turk J. Haematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.15420\/aer.2025.33","article-title":"The global impact of atrial fibrillation","volume":"14","author":"Karatela","year":"2025","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJM199512143332402","article-title":"Low-molecular-weight heparin for the treatment of acute ischemic stroke","volume":"333","author":"Kay","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J. ThrombHaemost"},{"key":"B42","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.rmed.2004.02.017","article-title":"Treatment of venous thromboembolism with low-molecular-weight heparin: a synthesis of the evidence published in systematic literature reviews","volume":"98","author":"Krishnan","year":"2004","journal-title":"Respir. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e005155","DOI":"10.1161\/JAHA.116.005155","article-title":"Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care","volume":"6","author":"Lane","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"109294","DOI":"10.1016\/j.thromres.2025.109294","article-title":"The efficacy and safety of low-molecular-weight heparins for venous thromboembolism prophylaxis in abdominal or pelvic cancer surgery: a systematic review and network meta-analysis of randomized controlled trials","volume":"249","author":"Liu","year":"2025","journal-title":"Thromb. Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.rec.2019.03.019","article-title":"Atrial fibrillation in active cancer patients: expert position paper and recommendations","volume":"72","author":"L\u00f3pez-Fern\u00e1ndez","year":"2019","journal-title":"Rev. Esp. Cardiol. Engl. Ed."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1002\/cncr.24665","article-title":"Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer","volume":"115","author":"Lyman","year":"2009","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/hematology.2024000566","article-title":"Practical guide to the diagnosis and management of heparin-induced thrombocytopenia","volume":"2024","author":"May","year":"2024","journal-title":"Hematol. Am. Soc. HematolEduc Program"},{"key":"B50","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.chest.2017.08.008","article-title":"Comparative effectiveness of enoxaparin vs dalteparin for thromboprophylaxis after traumatic injury","volume":"153","author":"Miano","year":"2018","journal-title":"Chest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40959-024-00243-z","article-title":"Crosslink between atrial fibrillation and cancer: a therapeutic conundrum","volume":"10","author":"Nardi","year":"2024","journal-title":"Cardiooncology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11606-016-3932-7","article-title":"Personalizing bridging anticoagulation in patients with nonvalvular atrial Fibrillation-a microsimulation analysis","volume":"32","author":"Pappas","year":"2017","journal-title":"J. Gen. Intern. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1182\/hematology.2022000411","article-title":"Evidence-based minireview: full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia","volume":"2022","author":"Patell","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1253\/circj.cj-12-1036","article-title":"Stroke and thromboembolism in atrial fibrillation","volume":"76","author":"Pisters","year":"2012","journal-title":"Circ. J."},{"key":"B55","volume-title":"Perioperative anticoagulation management. 2023 Jan 23.","author":"Polania Gutierrez","year":"2026"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1074562","DOI":"10.3389\/fcvm.2022.1074562","article-title":"Imaging and biophysical modelling of thrombogenic mechanisms in atrial fibrillation and stroke","volume":"9","author":"Qureshi","year":"2023","journal-title":"Front. Cardiovasc Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"205013","DOI":"10.1155\/2015\/205013","article-title":"Left atrial appendage: physiology, pathology, and role as a therapeutic target","volume":"2015","author":"Regazzoli","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1111\/jth.15052","article-title":"Anticoagulant and signaling functions of antithrombin","volume":"18","author":"Rezaie","year":"2020","journal-title":"J. ThrombHaemost"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0190324","DOI":"10.1371\/journal.pone.0190324","article-title":"Association of atrial fibrillation and cancer: analysis from two large population-based case-control studies","volume":"13","author":"Saliba","year":"2018","journal-title":"PLoS One"},{"key":"B60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1055\/s-2000-9497","article-title":"Comparative pharmacokinetics of LMWHs","volume":"26","author":"Samama","year":"2000","journal-title":"Semin. Thromb. Hemost."},{"key":"B61","doi-asserted-by":"publisher","first-page":"CD000024","DOI":"10.1002\/14651858.CD000024.pub3","article-title":"Anticoagulants for acute ischaemic stroke","author":"Sandercock","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15420\/ecr.2018.32.2","article-title":"AF in cancer patients: a different need for anticoagulation?","volume":"14","author":"Sanz","year":"2019","journal-title":"Eur. Cardiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1023\/a:1009823001707","article-title":"Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management","volume":"4","author":"Savelieva","year":"2000","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv."},{"key":"B65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3121\/cmr.2020.1546","article-title":"Efficacy and safety of perioperative bridging anticoagulation in patients with atrial fibrillation undergoing elective surgical procedures: a meta-analysis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin. Med. Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"878","DOI":"10.20452\/pamw.15315","article-title":"Oral anticoagulation in patients with active cancer and atrial fibrillation: current challenges","volume":"130","author":"Sorigue","year":"2020","journal-title":"Pol. Arch. Intern Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1200\/JOP.18.00592","article-title":"Atrial fibrillation and stroke risk in patients with cancer: a primer for oncologists","volume":"15","author":"Sorigue","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"B69","doi-asserted-by":"publisher","first-page":"g2116","DOI":"10.1136\/bmj.g2116","article-title":"Anticoagulation in atrial fibrillation","volume":"348","author":"Steinberg","year":"2014","journal-title":"BMJ"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s11239-025-03188-x","article-title":"Anticoagulant therapy in patients with cancer and thrombocytopenia","volume":"58","author":"Szmit","year":"2025","journal-title":"J. Thromb. Thrombolysis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3390\/ijerph20043491","article-title":"Long-term outcomes after stroke in patients with atrial fibrillation: a single center study","volume":"20","author":"Tracz","year":"2023","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B72","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/ijs.12007","article-title":"Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation","volume":"10","author":"Tu","year":"2015","journal-title":"Int. J. Stroke"},{"key":"B73","doi-asserted-by":"publisher","first-page":"S329","DOI":"10.1053\/hj.1998.v135.90304","article-title":"Pharmacology of the low-molecular-weight heparins","volume":"135","author":"Turpie","year":"1998","journal-title":"Am. Heart J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"ESC guidelines for the management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur. Heart J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.thromres.2021.11.026","article-title":"Drug-drug interactions: implications for anticoagulation, with focus in patients with cancer","volume":"213","author":"Wang","year":"2022","journal-title":"Thromb. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1046\/j.1365-2141.2003.04334.x","article-title":"Heparin-induced thrombocytopenia: pathogenesis and management","volume":"121","author":"Warkentin","year":"2003","journal-title":"Br. J. Haematol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: virchow's triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ageing\/afy180","article-title":"Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis","volume":"48","author":"Wilkinson","year":"2019","journal-title":"Age Ageing"},{"key":"B79","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","article-title":"Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism","volume":"41","author":"Witt","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.transci.2007.12.005","article-title":"Thrombin generation, fibrin clot formation and hemostasis","volume":"38","author":"Wolberg","year":"2008","journal-title":"TransfusApher Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"939","DOI":"10.12998\/wjcc.v10.i3.939","article-title":"Atrial fibrillation burden and the risk of stroke: a systematic review and dose-response meta-analysis","volume":"10","author":"Yang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"B82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcancer.2025.02.006","article-title":"Atrial fibrillation in cancer patients: epidemiology, identification and management","volume":"111","author":"Yu","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study","volume":"3","author":"Yun","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cjca.2017.12.008","article-title":"Assessment and management of the left atrial appendage thrombus in patients with nonvalvular atrial fibrillation","volume":"34","author":"Zhan","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B86","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"43","author":"Zirlik","year":"2017","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1853400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:43:07Z","timestamp":1791355387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1853400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":87,"alternative-id":["10.3389\/fphar.2026.1853400"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1853400","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1853400"}}